Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 2821 AL 2835

Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges

López ES, Machado ALL, Vidal LB, González-Pizarro R, Silva AD, Souto EB.

Curr Pharm Des. 2020;26(12):1235-1250. doi: 10.2174/1381612826666200218101231.

Disease Modification in Alzheimer's Disease: Current Thinking

Liu-Seifert H, Schumi J, Miao X, Tian Y, Rabbia M, Andersen SW, Wilson S, Li W, Entsuah R.

Ther Innov Regul Sci. 2020 Mar;54(2):396-403. doi: 10.1007/s43441-019-00068-4. Epub 2020 Jan 6.

Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer's Disease: A Re-Analysis of the CATIE-AD Study

Nagata T, Shinagawa S, Yoshida K, Noda Y, Shigeta M, Mimura M, Nakajima S.

J Clin Psychiatry. 2020 Feb 11;81(2):19m12961. doi: 10.4088/JCP.19m12961.

[Gene-specific treatment approaches in Alzheimer's disease and other tauopathies]

Feneberg E, Otto M.

Nervenarzt. 2020 Apr;91(4):312-317. doi: 10.1007/s00115-020-00872-6.

Human-Induced Pluripotent Stem Cells and Herbal Small-Molecule Drugs for Treatment of Alzheimer's Disease

Wuli W, Tsai ST, Chiou TW, Harn HJ.

Int J Mol Sci. 2020 Feb 16;21(4):1327. doi: 10.3390/ijms21041327.

LW-AFC, a new formula from the traditional Chinese medicine Liuwei Dihuang decoction, as a promising therapy for Alzheimer's disease: Pharmacological effects and mechanisms

Cheng X, Huang Y, Zhang Y, Zhou W.

Adv Pharmacol. 2020;87:159-177. doi: 10.1016/bs.apha.2019.10.005. Epub 2020 Jan 3.

Lemborexant: First Approval

Scott LJ.

Drugs. 2020 Mar;80(4):425-432. doi: 10.1007/s40265-020-01276-1.

Targeting Post-Translational Remodeling of Ryanodine Receptor: A New Track for Alzheimer's Disease Therapy?

Chami M, Checler F.

Curr Alzheimer Res. 2020;17(4):313-323. doi: 10.2174/1567205017666200225102941.

Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands

Iraji A, Khoshneviszadeh M, Firuzi O, Khoshneviszadeh M, Edraki N.

Bioorg Chem. 2020 Apr;97:103649. doi: 10.1016/j.bioorg.2020.103649. Epub 2020 Feb 4.

Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease

Li H, Liu Y, Tian D, Tian L, Ju X, Qi L, Wang Y, Liang C.

Eur J Med Chem. 2020 Apr 15;192:112163. doi: 10.1016/j.ejmech.2020.112163. Epub 2020 Feb 22.

Postmortem Analysis in a Clinical Trial of AAV2-NGF Gene Therapy for Alzheimer's Disease Identifies a Need for Improved Vector Delivery

Castle MJ, Baltanás FC, Kovacs I, Nagahara AH, Barba D, Tuszynski MH.

Hum Gene Ther. 2020 Apr;31(7-8):415-422. doi: 10.1089/hum.2019.367. Epub 2020 Mar 30.

Alzheimer's disease: microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation

Anwar S, Rivest S.

Expert Opin Ther Targets. 2020 Apr;24(4):331-344. doi: 10.1080/14728222.2020.1738391. Epub 2020 Mar 12.

Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease

Ceyzériat K, Zilli T, Millet P, Frisoni GB, Garibotto V, Tournier BB.

Curr Alzheimer Res. 2020;17(2):112-125. doi: 10.2174/1567205017666200304085513.

Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential

Mi Y, Qi G, Brinton RD, Yin F.

Antioxid Redox Signal. 2021 Mar 10;34(8):611-630. doi: 10.1089/ars.2020.8070. Epub 2020 Apr 21.

Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs

Ihara M, Saito S.

J Alzheimers Dis. 2020;74(4):1013-1028. doi: 10.3233/JAD-200049.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias